Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more
Market Cap & Net Worth: Cinclus Pharma (CINPHA)
Cinclus Pharma (ST:CINPHA) has a market capitalization of $71.69 Million (Skr804.17 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21519 globally and #238 in its home market, demonstrating a 3.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cinclus Pharma's stock price Skr17.28 by its total outstanding shares 46537789 (46.54 Million).
Cinclus Pharma Market Cap History: 2024 to 2026
Cinclus Pharma's market capitalization history from 2024 to 2026. Data shows change from $88.69 Million to $71.69 Million (-39.93% CAGR).
Cinclus Pharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cinclus Pharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CINPHA by Market Capitalization
Companies near Cinclus Pharma in the global market cap rankings as of March 19, 2026.
Key companies related to Cinclus Pharma by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Cinclus Pharma Historical Marketcap From 2024 to 2026
Between 2024 and today, Cinclus Pharma's market cap moved from $88.69 Million to $ 71.69 Million, with a yearly change of -39.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr71.69 Million | -10.28% |
| 2025 | Skr79.90 Million | -9.92% |
| 2024 | Skr88.69 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cinclus Pharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $71.69 Million USD |
| MoneyControl | $71.69 Million USD |
| MarketWatch | $71.69 Million USD |
| marketcap.company | $71.69 Million USD |
| Reuters | $71.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.